interval increased enhancement of the left biliary ductal segment and a 2.7 Â 2.6 caudate lobe liver lesion (Fig. 5 ). This interval decrease in tumor size was likely due to the systemic effects of his chemotherapy.
The patient returned for ERCP with locoregional RFA after his imaging results were obtained (Video 1, available online at www.VideoGIE.org). After stent removal, wireguided cannulation was performed with a standard bowing sphinctertome and a 0.035 Â 260 cm wire. A cholangiogram then demonstrated persistent stenosis of the left hepatic duct. The duct was swept in an attempt to clear debris, which may have been causing the residual stenosis. However, several sweeps demonstrated no visible debris.
After the balloon sweep, a cholangioscope was inserted into the biliary system, revealing papillary irregularities and localized intraductal narrowing in the left main hepatic duct.
The cholangioscope was then withdrawn, and the intraductal RFA (IDRFA) probe was inserted through the biliary orifice up into the left main hepatic duct above the area of stenosis. Using a bipolar setting effect 8 at 7 watts, we performed ablation for a total of 90 seconds. This ablation setting is recommended for left and right ductal therapy as opposed to effect 8 at 10 watts for common ductal therapy (Fig. 6 ). After the probe was held for 60 seconds after the first treatment, the probe was then moved distally toward the main hepatic duct, allowing for overlap of the initial site of locoregional therapy, and a second treatment of RFA was applied (Fig. 7) . The bile duct was then re-explored with the cholangioscope and advanced to the left main hepatic duct, demonstrating interlacing white tissue and absence of papillary changes at the site of treatment. Additionally, there was no evidence of hemorrhage or perforation. The cholangioscope was again removed, and the duct again swept, now revealing an evident tissue cast after RFA.
Finally, a new 10F Â 12 cm double-flapped plastic biliary stent was placed, crossing the left hepatic duct.
Six months later, after the patient completed a second cycle of chemotherapy, CT, in comparison with the patient's prior imaging, demonstrated an interval decrease in the size of the caudate lobe lesion to approximately 1.7 Â 2.1 cm (previously 2.6 Â 2.7 cm), with post-RFA changes around the left hepatic duct and an intact stent with pneumobilia (Fig. 8) . This decrease in tumor size was likely due to systemic chemotherapy.
Repeated ERCP was 6 months after the RFA was performed, during which the cholangiogram showed improvement in the left hepatic ductal stenosis (Fig. 9) . A cholangioscope was used, the left duct remained patent, and poststenting inflammatory changes were visible. His liver function values remained normal, and he has had no hospitalizations or obstructive biliary adverse events.
Preclinical data in animal models have confirmed the safety and efficacy of RFA in this setting. 3, 4 An additional open-labeled study in humans demonstrated clinical safety, leading to subsequent device approval. 5, 6 Since the availability of this probe, retrospective series have evaluated its efficacy in biliary neoplasms not amenable to surgery. These retrospective data have alluded to the benefit of RFA in improving stenosis, the duration of stent patency, and survival. [7] [8] [9] [10] [11] In this case, the appearance of postintraductal RFA was an interesting finding as seen by a cobweb appearance on cholangioscopy.
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